Biome Australia (ASX: BIO) — Company Overview, News & Financial Data
Biome Australia is an Australian microbiome health company that develops, commercialises, and markets live biotherapeutics and complementary medicines.
Biome Australia
Biome Australia is an Australian microbiome health company that develops, commercialises, and markets live biotherapeutics and complementary medicines. The company formulates evidence-based probiotic products targeted at specific health conditions, including gastrointestinal health, mental wellbeing, skin conditions, and immune support. Its products are distributed through community pharmacies, health food stores, and medical practitioners across Australia, New Zealand, and international markets. Biome Australia conducts clinical trials and research partnerships to validate the therapeutic efficacy of its targeted probiotic formulations for consumer and practitioner health channels.
Snapshot
Operations
Products and/or services of Biome Australia
- Practitioner-Only Probiotics: Formulated targeted live biotherapeutic products sold under practitioner-only brands to support gut health, digestive function, and microbiome balance in patients through pharmacy and clinic recommendation channels.
- Mental Wellbeing Probiotics: Clinically trial-backed live biotherapeutic strains formulated to support mood, stress response, sleep quality, and cognitive performance via brain-gut axis modulation distributed to health practitioners and retail pharmacies.
- Dermatological Probiotics: Specialized probiotic formulations targeted at skin condition management including eczema, acne, and inflammatory dermatological disorders by balancing systemic and cutaneous microbiome profiles across primary pharmacy and clinical practitioner networks.
- Pediatric and Maternal Health Formulations: Specialized live biotherapeutic supplements designed for infant, child, and maternal health, supporting immune development, early gut microbiota colonization, and pregnancy wellbeing across healthcare and pharmacy distribution channels.
- Digestive and Metabolic Health Products: Targeted biotherapeutic therapies designed to relieve symptoms of irritable bowel syndrome, constipation, metabolic dysbiosis, and systemic metabolic imbalance for consumer healthcare and clinical practitioner applications across retail networks.
- International Pharmacy Distribution: Commercial distribution networks and trade distribution partnerships supplying evidence-based biotherapeutic product ranges to retail pharmacy chains, independent stockists, and health practitioners across New Zealand, Europe, and the United Kingdom.
Biome Australia executive team
- Blair William Brabin Vega NorfolkMD, CEO & Director
- Lauren DwyerChief Financial Officer
- Jaroslav Haman BoublikChief Science Officer & Member of Scientific Advisory Board
- George LazarouCompany Secretary
Latest news about Biome Australia
Biome Australia launches new probiotic products
AustraliaBiome Australia reports sales revenue of $23.9M for FY26
AustraliaBiome launches international BMB18 probiotic clinical trial
AustraliaBiome secures exclusive Probiotical supply extension through 2028
AustraliaBiome books record H1 profit growth
AustraliaBiome Australia greenlit for major probiotic trial
Australia
Recent announcements
What Biome Australia (BIO) has told the market, newest first.
- Change of Auditor
Key financials
Reported results for Biome Australia.
- Market cap
- 83.3M
- Revenue (TTM)
- 23.9M
- P/E ratio
- 18.0
- EPS (diluted, TTM)
- 0.0
- Dividend yield
- —
- Profit margin
- 15.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 23.9M | 1.8M | 3.6M | |
| 18.4M | 278.5K | 214.7K | |
| 13M | -1.7M | -1.7M | |
| 7.2M | -3.3M | -3.1M |